The global digital dose inhaler market size reached US$ 2.9 Billion in 2022. Looking forward, the analyst expects the market to reach US$ 6.7 Billion by 2028, exhibiting a growth rate (CAGR) of 14.6% during 2023-2028.
Digital dose inhalers are utilized to provide a simple, accurate, and reliable dose counter, which enables asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy. These inhalers comprise sensors that record the time of medication administration and provide a low-dose warning indicator. They also offer a large display for easy accessibility and comprehension by varied patient populations. Nowadays, digital dose inhalers are integrated with Bluetooth technology that assists in pairing with a tablet, smartphone, or computer wirelessly to enable the automatic transfer of data.
Digital Dose Inhaler Market Trends:
A considerable rise in the number of individuals diagnosed with chronic respiratory diseases (CRDs), such as bronchial asthma, lung disorders, pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD), represents one of the key factors driving the demand for digital dose inhalers worldwide. Additionally, the risk of developing CRDs is increasing around the world on account of the growing number of tobacco smokers, rising levels of air pollution, and occupational dust exposure in the agriculture, forestry, and mining settings. This, in turn, is bolstering the market growth. Apart from this, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are introducing several programs to spread awareness about CRDs and the available treatments. Moreover, dry powder inhaler (DPI) systems are gaining traction as they target the delivery of fine drug particles to the deeper airways in the lungs. As a result, several manufacturers are offering capsule-based and disposable DPI devices with improved reliability, consistency, and cost-effectiveness, which is driving the market. Furthermore, favorable reimbursement policies available to the patients via government-sponsored plans and individual insurance and employee policies are boosting the treatment rates of respiratory disorders. This, in turn, is projected to stimulate the growth of the market.
Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global digital dose inhaler market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type and product.
Breakup by Type:
Breakup by Product:
Metered Dose Inhaler
Dry Powder Inhaler
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips N.V., Lupin Limited, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG Switzerland and Teva Pharmaceutical Industries Ltd.
Key Questions Answered in This Report
1. What was the size of the global digital dose inhaler market in 2022?
2. What is the expected growth rate of the global digital dose inhaler market during 2023-2028?
3. What are the key factors driving the global digital dose inhaler market?
4. What has been the impact of COVID-19 on the global digital dose inhaler market?
5. What is the breakup of the global digital dose inhaler market based on the type?
6. What is the breakup of the global digital dose inhaler market based on the product?
7. What are the key regions in the global digital dose inhaler market?
8. Who are the key players/companies in the global digital dose inhaler market?